JPWO2023081317A5 - - Google Patents
Info
- Publication number
- JPWO2023081317A5 JPWO2023081317A5 JP2024527078A JP2024527078A JPWO2023081317A5 JP WO2023081317 A5 JPWO2023081317 A5 JP WO2023081317A5 JP 2024527078 A JP2024527078 A JP 2024527078A JP 2024527078 A JP2024527078 A JP 2024527078A JP WO2023081317 A5 JPWO2023081317 A5 JP WO2023081317A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- complementarity determining
- determining region
- pharmaceutical composition
- chain complementarity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163275890P | 2021-11-04 | 2021-11-04 | |
| US63/275,890 | 2021-11-04 | ||
| PCT/US2022/048887 WO2023081317A2 (en) | 2021-11-04 | 2022-11-03 | Treatment of cancer with nk cells and multispecific engagers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024542159A JP2024542159A (ja) | 2024-11-13 |
| JP2024542159A5 JP2024542159A5 (https=) | 2025-11-12 |
| JPWO2023081317A5 true JPWO2023081317A5 (https=) | 2025-11-12 |
Family
ID=86242049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527078A Pending JP2024542159A (ja) | 2021-11-04 | 2022-11-03 | Ｎｋ細胞と多重特異性エンゲージャーとによるがんの処置 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240424099A1 (https=) |
| EP (1) | EP4426350A4 (https=) |
| JP (1) | JP2024542159A (https=) |
| KR (1) | KR20240107147A (https=) |
| CN (1) | CN118613271A (https=) |
| AU (1) | AU2022380926A1 (https=) |
| CA (1) | CA3237016A1 (https=) |
| IL (1) | IL312555A (https=) |
| WO (1) | WO2023081317A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018124766A2 (ko) | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| EP3633029A4 (en) | 2017-05-26 | 2021-06-09 | Green Cross Lab Cell Corporation | METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL |
| US12116417B2 (en) | 2017-11-14 | 2024-10-15 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| MY199770A (en) | 2018-11-14 | 2023-11-22 | Green Cross Lab Cell Corp | Method for culturing cord blood-derived natural killer cells using transformed t cells |
| JP2024540347A (ja) * | 2021-11-09 | 2024-10-31 | ウーゲン，インコーポレイテッド | 記憶ｎｋ細胞と抗癌性二重特異性分子とによる組み合わせ癌療法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2027291A2 (en) * | 2006-04-27 | 2009-02-25 | Pikamab, Inc. | Methods and compositions for antibody therapy |
| US20130011376A1 (en) * | 2009-12-29 | 2013-01-10 | Gamida Cell Ltd. | Methods for Enhancing Natural Killer Cell Proliferation and Activity |
| JP7237449B2 (ja) * | 2015-02-27 | 2023-03-13 | アイセル・ジーン・セラピューティクス・エルエルシー | 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| ES2754557T3 (es) * | 2015-05-04 | 2020-04-20 | Affimed Gmbh | Combinación de un anticuerpo CD30XCD16A con un anticuerpo antagonista anti-PD-1 para terapia |
| PT3843757T (pt) * | 2018-08-27 | 2024-07-08 | Affimed Gmbh | Células nk criopreservadas pré-carregadas com uma construção de anticorpo |
| EP4045539A4 (en) * | 2019-10-17 | 2024-03-13 | Fate Therapeutics, Inc. | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof |
-
2022
- 2022-11-03 JP JP2024527078A patent/JP2024542159A/ja active Pending
- 2022-11-03 EP EP22890795.2A patent/EP4426350A4/en active Pending
- 2022-11-03 KR KR1020247018559A patent/KR20240107147A/ko active Pending
- 2022-11-03 WO PCT/US2022/048887 patent/WO2023081317A2/en not_active Ceased
- 2022-11-03 AU AU2022380926A patent/AU2022380926A1/en active Pending
- 2022-11-03 US US18/707,276 patent/US20240424099A1/en active Pending
- 2022-11-03 IL IL312555A patent/IL312555A/en unknown
- 2022-11-03 CA CA3237016A patent/CA3237016A1/en active Pending
- 2022-11-03 CN CN202280087592.8A patent/CN118613271A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7575104B2 (ja) | ナチュラルキラー細胞およびキメラ抗原受容体改変された細胞の拡大増殖 | |
| ES2926384T3 (es) | Métodos para mejorar la eficacia de células inmunitarias terapéuticas | |
| CN113383071A (zh) | 用于t细胞工程化的组合物和方法 | |
| TW202241508A (zh) | 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法 | |
| CA3118616A1 (en) | Selection of improved tumor reactive t-cells | |
| JP7834029B2 (ja) | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用 | |
| TW202304480A (zh) | 腫瘤浸潤淋巴球（ｔｉｌ）中之與ｃｄ３９／ｃｄ６９選擇及基因剔除相關之ｔｉｌ擴增之方法 | |
| CA3134308A1 (en) | Rituximab-resistant chimeric antigen receptors and uses thereof | |
| US20230293685A1 (en) | Selection of improved tumor reactive t-cells | |
| KR20210033941A (ko) | 개선된 t-세포 요법 | |
| TW202239415A (zh) | 腫瘤浸潤性淋巴球療法與ｃｔｌａ－４及ｐｄ－１抑制劑組合之治療 | |
| WO2005009466A1 (en) | Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells | |
| JPWO2023081317A5 (https=) | ||
| CA3132509A1 (en) | Methods of manufacturing allogeneic car t cells | |
| JPWO2023278811A5 (https=) | ||
| JPWO2022216837A5 (https=) | ||
| KR20260024372A (ko) | 다중-수용체 자연 살해 세포 | |
| JPWO2022216826A5 (https=) | ||
| JPWO2021163391A5 (https=) | ||
| JPWO2022216831A5 (https=) | ||
| EP4519418A1 (en) | Methods for improving t cell efficacy | |
| KR20230007384A (ko) | 치료 방법 | |
| JPWO2022216815A5 (https=) | ||
| US20260061052A1 (en) | Processes for generating til products using pd-1/tigit talen double knockdown | |
| TW202426633A (zh) | 使用ｐｄ－１／ｔｉｇｉｔ ｔａｌｅｎ雙重基因減弱生成ｔｉｌ產物之方法 |